Cardiovascular Business spoke with cardiologist Daniel Judge, MD, about the long-term benefits of acoramidis, a new drug therapy that just received FDA approval to treat transthyretin amyloid cardiomyopathy.

Martha Gulati, MD, spoke to Cardiovascular Business at AHA Scientific Sessions 2024 about key developments in obesity treatment and CVD prevention.

Deepak Bhatt, MD, MPH, MBA, spoke to Cardiovascular Business about the growing importance of evaluating coronary inflammation in heart patients. There has been an explosion of interest in this area since the FDA's 2023 clearance of colchicine.

Providing radiologists with key details about the patient's symptoms can go a long way toward improving the quality of their work. 

Hadley Wilson, MD, spoke to Cardiovascular Business at the three-day event to discuss key late-breaking studies and trends. Topics included new drug treatments, AI and much more.

Researchers took a closer look at the effectiveness of redo TAVR, implanting Sapien 3 valves into a variety of explanted CoreValve and Evolut valves.

The hope is that by creating detectors that are more sensitive, less ionizing radiation will be needed to produce diagnostic quality imaging.

A recent analysis of an already CE-marked, AI-based system that identifies pneumothorax on chest radiographs revealed a weak point in what has largely been considered a reliable support tool.